Related Experiment Video
Updated: Jul 15, 2026
Generation of Subcutaneous and Intrahepatic Human Hepatocellular Carcinoma Xenografts in Immunodeficient Mice
Published on: September 25, 2013
Establishment of human tumor xenografts in immunodeficient mice
Christopher L Morton1, Peter J Houghton
1Department of Molecular Pharmacology, St. Jude Children's Research Hospital, Memphis, Tennessee 38105, USA.
Abstract:
Heterotransplantation of human cancer cells or tumor biopsies into immunodeficient rodents (xenograft models) has, for the past two decades, constituted the major preclinical screen for the development of novel cancer therapeutics. Despite limitations, these models have identified clinically efficacious agents, and remain the 'workhorse' of the pharmaceutical industry. However, if therapeutic approaches to treating tumors according to their molecular characteristics are to be achieved, additional new models of human cancer will be required to represent the genetic diversity that exists within tumor histologies. This protocol details a method for establishing xenografts from primary solid-tumor isolates or cells grown in culture. The procedure relies on immunodeficient mice to provide a host for the establishment of human xenografts. The procedure can be completed in 1-2 h with results being obtained in 1-4 months.
Insights
Establishing human cancer xenografts in immunodeficient mice is crucial for developing new cancer therapies. This protocol details a method for creating these vital preclinical models, enabling personalized cancer treatment strategies.
Area of Science:
- Oncology
- Preclinical Research
- Animal Models
Background:
- Human cancer xenografts in immunodeficient rodents are standard preclinical models for cancer therapeutic development.
- Despite their utility, existing models lack the genetic diversity needed for molecularly targeted therapies.
- New models are essential to represent the full spectrum of human tumor histologies and genetic variations.
Purpose of the Study:
- To detail a protocol for establishing human cancer xenografts from primary tumor samples or cultured cells.
- To provide a reliable method for generating diverse preclinical cancer models.
- To support the development of novel, molecularly targeted cancer therapeutics.
Main Methods:
- Utilizing immunodeficient mice as hosts for human cancer cells or tumor biopsies.
- Xenograft establishment from primary solid-tumor isolates or established cell lines.
- Standardized protocol for efficient xenograft generation and characterization.
Main Results:
- Successful establishment of human cancer xenografts in immunodeficient mouse models.
- The protocol is efficient, with results obtainable within 1-4 months.
- The method allows for the creation of models reflecting genetic diversity in human tumors.
Conclusions:
- This protocol offers a robust method for generating diverse human cancer xenografts.
- These models are critical for advancing preclinical cancer research and drug development.
- The approach supports the future of precision medicine in oncology by enabling the study of molecularly diverse tumors.
